The second group of ICIs includes anti-PD-L1 antibodies, including atezolizumab, durvalumab, and avelumab, which block the ligand for PD-1–PD-L1—on tumor cells and tumor-infiltrating immune cells2,3. Here, PDCD1 is linked to neoplasm.